{"entity":{"id":"radiomedix","kind":"company","name":"RadioMedix","aka":[],"tldr":"RadioMedix is developing AlphaMedix (212Pb-DOTAMTATE) with Orano Med, the first targeted alpha therapy to receive FDA Breakthrough designation.","summary":"RadioMedix, based in Houston, is developing AlphaMedix, or 212Pb-DOTAMTATE, with Orano Med, the first targeted alpha therapy to receive FDA Breakthrough designation. AlphaMedix met all primary efficacy endpoints in phase 2, with a 60 percent objective response rate in PRRT-naive gastroenteropancreatic neuroendocrine tumour patients reported at ESMO 2025, was licensed to Sanofi with Orano Med in 2024, and has its next trial planned for late 2026; the company marked twenty years at SNMMI 2026. OnCo links it to neuroendocrine tumours, to targeted alpha therapy and peptide receptor radionuclide therapy, to somatostatin receptor 2 as a target, and to Orano Med and Sanofi. Whether a lead-212 alpha emitter beats existing beta-emitter PRRT in a randomised trial is the open question. 212Pb-DOTAMTATE has its own page.","asOf":"2026-09-04","links":[{"label":"Sanofi licensing agreement","url":"https://www.sanofi.com/en/media-room/press-releases/2024/2024-09-12-05-00-00-2944919"}],"tags":[],"related":[],"cancers":["neuroendocrine"],"sections":["radiopharma"],"technologies":["targeted-alpha-therapy"],"targets":["sstr2"],"drugs":[],"companies":["orano-med","sanofi"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Houston, TX","country":"US","companyType":"radiopharma","website":"https://www.radiomedix.com","investors":[],"funding":[]},"route":"/companies/radiomedix/","neighbours":{"cancer":[{"id":"neuroendocrine","kind":"cancer","name":"Neuroendocrine tumours","route":"/cancers/neuroendocrine/"}],"section":[{"id":"radiopharma","kind":"section","name":"Radiopharmaceuticals & Theranostics","route":"/fronts/radiopharma/"}],"technology":[{"id":"cyclotron-isotope-production","kind":"technology","name":"Cyclotron isotope production (F-18, Ga-68, Cu-64, Zr-89, At-211)","route":"/technologies/cyclotron-isotope-production/"},{"id":"prrt","kind":"technology","name":"Peptide receptor radionuclide therapy (PRRT)","route":"/technologies/prrt/"},{"id":"targeted-alpha-therapy","kind":"technology","name":"Targeted alpha therapy","route":"/technologies/targeted-alpha-therapy/"}],"target":[{"id":"sstr2","kind":"target","name":"Somatostatin receptor 2","route":"/targets/sstr2/"}],"company":[{"id":"orano-med","kind":"company","name":"Orano Med","route":"/companies/orano-med/"},{"id":"sanofi","kind":"company","name":"Sanofi","route":"/companies/sanofi/"}],"drug":[{"id":"alphamedix","kind":"drug","name":"212Pb-DOTAMTATE","route":"/drugs/alphamedix/"}],"trial":[{"id":"alphamedix-02","kind":"trial","name":"ALPHAMEDIX-02","route":"/trials/alphamedix-02/"},{"id":"nct03673943","kind":"trial","name":"Imaging of Patients With Known or Suspected Somatostatin Receptor Positive Neuroendocrine Tumors Using Cu64-DOTATATE","route":"/trials/nct03673943/"}]}}